Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells
about
A transposon and transposase system for human applicationHematopoietic stem cell gene therapy:assessing the relevance of preclinical modelsRetroviral integrations in gene therapy trialsHematopoietic stem cell engineering at a crossroadsRevealing domain structure through linker-scanning analysis of the murine leukemia virus (MuLV) RNase H and MuLV and human immunodeficiency virus type 1 integrase proteinsReal-time definition of non-randomness in the distribution of genomic eventsIntegration site selection by retroviral vectors: molecular mechanism and clinical consequences.Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils.Long-term vector integration site analysis following retroviral mediated gene transfer to hematopoietic stem cells for the treatment of HIV infection.Transcription factor binding sites are genetic determinants of retroviral integration in the human genome.Identification of two critically deleted regions within chromosome segment 7q35-q36 in EVI1 deregulated myeloid leukemia cell linesSelf-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.Genotoxic potential of lineage-specific lentivirus vectors carrying the beta-globin locus control region.Vector integration and tumorigenesis.Neonatal intravenous injection of a gammaretroviral vector has a low incidence of tumor induction in mice.Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1.Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome.Large animal models of hematopoietic stem cell gene therapy.Analyzing the number of common integration sites of viral vectors--new methods and computer programs.Repetitive busulfan administration after hematopoietic stem cell gene therapy associated with a dominant HDAC7 clone in a nonhuman primate.Ex vivo expansion of retrovirally transduced primate CD34+ cells results in overrepresentation of clones with MDS1/EVI1 insertion sites in the myeloid lineage after transplantation.BCL2A1a over-expression in murine hematopoietic stem and progenitor cells decreases apoptosis and results in hematopoietic transformation.Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.Tracking of specific integrant clones in dogs treated with foamy virus vectors.Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vectorNo evidence for clonal selection due to lentiviral integration sites in human induced pluripotent stem cells.Retroviral vectors: post entry events and genomic alterations.Retroviral gene therapy for X-linked chronic granulomatous disease: results from phase I/II trial.Insertion sites in engrafted cells cluster within a limited repertoire of genomic areas after gammaretroviral vector gene therapyRetroviral vector insertion sites associated with dominant hematopoietic clones mark "stemness" pathways.Pigtailed macaques as a model to study long-term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies.Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cellsAcute myeloid leukemia is associated with retroviral gene transfer to hematopoietic progenitor cells in a rhesus macaque.Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity.Predicting preferential DNA vector insertion sites: implications for functional genomics and gene therapy.
P2860
Q24630047-46CBDA07-2A1B-4BF9-BBBD-5EA206C33E75Q26859147-0A924865-F115-443D-BB63-5912C66331B2Q26991660-C196D5BE-EE45-4C92-B2CA-96DDB82B38E5Q27001570-3E3E3BDB-CA79-4E52-A30A-01D2D4B550B7Q33257614-435FF84D-AEEA-486B-9971-363836E2BF2DQ33288965-8A8B1E64-923C-4428-8AF1-F0B630127A9AQ33340808-B0B303DC-E139-4590-83CE-1D1DFBE5738FQ33387329-345A5C9C-010F-4F65-A989-8D065202D8EBQ33400359-A2C720F2-FAD3-4F44-8EF8-D595C22E5792Q33411772-AF6E70C9-3A20-412C-AB5A-57D351225E5EQ33525049-D8FBFC2B-0DCF-48BC-BAEB-24A8FB2CFEC1Q33713150-2B4E9ECC-EBE1-49BA-85D7-00FA3BC6D41EQ33713196-C43B4267-F09E-4906-86B5-E022FAF50675Q33782783-C3384E30-490B-4220-9354-38C19F70DD4AQ33936562-BC5585C7-954E-49C0-A3AC-0B7712379082Q33984313-7F45E7CC-086C-4003-BCE1-34C379447ECBQ34006457-06E78F1A-6363-4AF9-A3AB-E16270C1037AQ34039922-F1331C9D-3723-438D-8E1C-5CD2628E28A2Q34055417-C0734959-6C64-4340-B9E8-BBADD5A0C5A2Q34123262-2FF313CA-36A7-419C-B03D-1CF1374534BCQ34209811-75CEAD0D-3DD2-4553-B263-4A0F5BE1D2D0Q34464894-88B724AF-5656-4C3C-A948-444D7D9BDE38Q34508425-7B22AEFE-7277-456A-93A4-10236F5ED0CEQ34589239-66E53E35-9314-4B2F-9A8D-5982A68812A4Q34692989-D1FDACF1-9903-47D3-A884-D8A3D34670A1Q35215395-863E38D9-4728-4BC8-8C68-4E9789CA19A2Q35261336-21C34BE0-7117-41B5-87BB-AA57F5717C3AQ35568541-8ABFD859-A285-4C85-8F82-348F29697B17Q35568549-E980874A-02AC-49A2-A186-6007E1B5054DQ35642820-4C837CA7-D9F9-4391-A039-F502BFE38D25Q35664334-34109E46-1B29-495D-AA57-1E595A06189CQ35847760-25DE456E-9581-439D-8D08-4675C7EB958BQ35848273-2A478505-9149-4902-903E-CA7A3E13F375Q35849232-4129AE2A-5561-4E37-B1C1-315FF4BF1530Q35849315-4A62A50C-F2FC-4935-AFC2-1446D320E8E3Q35916092-EE6ECA48-B66B-4FBD-9A5B-7B2CA35F3423Q35916142-6FEBDE19-BC98-4A33-8A34-F3ECC1F41DD0Q35916190-8F315DAD-3294-4075-95F3-3252D801D5EDQ36166303-868C84FD-7B16-4034-85D3-39A271226507Q36187534-A81BF9A3-F3E4-4772-98C4-188E88685F0A
P2860
Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Recurrent retroviral vector in ...... an primate hematopoietic cells
@ast
Recurrent retroviral vector in ...... an primate hematopoietic cells
@en
type
label
Recurrent retroviral vector in ...... an primate hematopoietic cells
@ast
Recurrent retroviral vector in ...... an primate hematopoietic cells
@en
prefLabel
Recurrent retroviral vector in ...... an primate hematopoietic cells
@ast
Recurrent retroviral vector in ...... an primate hematopoietic cells
@en
P2093
P2860
P1433
P1476
Recurrent retroviral vector in ...... an primate hematopoietic cells
@en
P2093
Boris Calmels
Cole Ferguson
Hyeoung-Joon Kim
Keiko Akagi
Manfred Schmidt
Marion Faulhaber
Mikko O Laukkanen
Peiman Hematti
Rima Adler
Robert E Donahue
P2860
P304
P356
10.1182/BLOOD-2005-03-1115
P407
P577
2005-06-02T00:00:00Z